Clinical trials: Vaccines
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
The main purpose of this study is to use an investigational urine assay to estimate the proportion of pneumonia in adults 50 years or older in different areas throughout the US that is caused by certain types of the bacteria…
- Trial name
- NCT01086397
- Testing
- Urine sample collection
- Where
- 14 sites in United States
- Volunteers
- 782 people
- Sponsor
- Pfizer
13-valent Pneumococcal Vaccine, Immunization
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
This is an open-label study (a study in which the doctors and participants know which drug or vaccine is being administered) in children who previously received a 4-dose series of a pneumococcal conjugate vaccine (PnC) during…
- Conditions
- 13-valent Pneumococcal Vaccine, Immunization, Safety, Antibody Response
- Trial name
- NCT01026038
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 25 sites in France
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Pfizer
Botulism Vaccine
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
- Trial name
- NCT00764634
- Testing
- rBV A/B-40 vaccine
- Where
- 6 sites in United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Pneumococcal Conjugate Vaccine
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who…
- Trial name
- PILOT (NCT00824850)
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza Vaccines
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly
A controlled, double-blind study to determine the immunogenicity and safety of influenza cell derived vaccine in elderly subjects.
- Trial name
- NCT01013675
- Testing
- Influenza Vaccine
- Where
- 12 sites in Czechia, Estonia and 1 more
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Vaccines, Pneumococcal
Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico
The purpose of this study will be to evaluate safety, tolerability and immunogenicity of 13-valent pneumococcal vaccine in healthy infants given with routine pediatric vaccinations in Mexico.
- Trial name
- NCT00708682
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 9 sites in Mexico
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Vaccines
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
The purposes of this study are to evaluate the safety of 13-valent pneumococcal Conjugate Vaccine (13vPnC) in children who have already been vaccinated with Prevenar.
- Trial name
- NCT00824655
- Testing
- 13vPnC
- Where
- 7 sites in Sweden
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil
The purpose of this study will be to analyze 13-valent pneumococcal vaccine given to healthy infants in Brazil for safety and tolerability, and to determine the immune response to the vaccines.
- Trial name
- NCT00676091
- Testing
- 13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnc)
- Where
- 4 sites in Brazil
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Vaccines
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
- Trial name
- NCT00574548
- Testing
- 13 valent Pneumococcal Conjugate Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine
- Where
- 6 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Vaccine
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly…
- Trial name
- NCT00689351
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 6 sites in South Korea
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
The purpose of this study will be to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in Canada.
- Trial name
- NCT00475033
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 11 sites in Canada
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to…
- Trial name
- NCT00500357
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 16 sites in South Africa
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Viral Hepatitis Vaccines, Hepatitis A
Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis
The purpose of this study is to determine the seroprevalence of Hepatitis A Virus (HAV), Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Herpes Simplex (HSV) and Bordetella pertussis (BP)infections in Mexico.
- Conditions
- Viral Hepatitis Vaccines, Hepatitis A, Cytomegalovirus, Varicella-Zoster Virus
- Trial name
- NCT01160081
- Testing
- Serum sample
- Where
- Mexico
- Volunteers
- 3,658 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccines, Pneumococcal Conjugate Vaccine
Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
To collect post-marketing information on the safety of Prevenar in Filipino patients
- Trial name
- NCT00683410
- Testing
- Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)
- Where
- Philippines
- Volunteers
- 3,366 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
There is evidence that aluminum phosphate (AlPO4) contained as an adjuvant in conjugate vaccines enhances the immune response in infants. There is no data so far evaluating whether this also applies to adults.
- Trial name
- NCT00269672
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Volunteers
- 915 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Seasonal Influenza, Vaccine
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008
Annual trial for registration of trivalent split influenza vaccine with the strain composition of the season 2007/2008 in healthy adult and elderly subjects
- Trial name
- NCT00498303
- Testing
- trivalent split influenza vaccine
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Novartis
Pandemic Influenza Vaccine, Prevention
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1) vaccine (whole-virion, aluminium-adjuvanted).
- Conditions
- Pandemic Influenza Vaccine, Prevention, Pandemic Influenza
- Trial name
- NCT00660257
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Vaccines, Pneumococcal, Vaccines, Pneumococcal Conjugate Vaccine
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children
To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization.
- Trial name
- NCT00580684
- Testing
- pneumococcus conjugate vaccine 7 valent to reduce carriage
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating Prevenar Immunogenicity in High Risk Children
To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with immunodeficiency condition. To evaluate tolerability of Prevenar® in that population.
- Trial name
- NCT00581620
- Testing
- pneumococcus conjugate vaccine
- Volunteers
- 160 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer